AB055. Infantile high-grade glioma (IHG)—a case series of Hong Kong experience
Abstract

AB055. Infantile high-grade glioma (IHG)—a case series of Hong Kong experience

Sau Ning Sarah Lau1, King Fai Kevin Cheng1, Wai Shing Wilson Ho1, Tak Loi Dennis Ku2, Chi Fung Godfrey Chan2

1Department of Neurosurgery, Hong Kong Children’s Hospital, Hong Kong, China; 2Haematology & Oncology/Solid Tumour & Neuro-Oncology Team, Department of Paediatrics and Adolescent Medicine, Hong Kong Children’s Hospital, Hong Kong, China

Correspondence to: Sau Ning Sarah Lau, MB, BChir (Cantab). Department of Neurosurgery, Hong Kong Children’s Hospital, Block B 9/F, 1 Shing Cheong Road, Kowloon Bay, Kowloon, Hong Kong, China. Email: sarahsnlau@hotmail.com.

Background: Infantile high-grade glioma (IHG) is diagnosed in patients less than 12 months of age. Studies have shown that it displays a more stable genome and is usually single mutation-driven. The most identifiable mutations are receptor tyrosine kinase (RTK) fusion, such as neurotrophic tyrosine receptor kinase (NTRK) family, reactive oxygen species (ROS1), anaplastic lymphoma kinase (ALK), and mesenchymal-epithelial transition (MET) factor. The current principal treatment remains to be surgery, but it is challenging for a complete resection due to hemispheric involvement. Use of chemotherapeutic drugs for IHG is still under debate, with targeted therapy showing efficacy in promoting tumor shrinkage. Despite being a challenging central nervous system (CNS) tumor, the overall survival of IHG is superior to other high-grade gliomas.

Case Description: This is a retrospective review of local IHG patients and their outcome. Up till the end of 2022, we identified eight IHG patients in our local data. Mean age of diagnosis was 3 months. There were four males and four females. Seven patients had histological diagnosis of glioblastoma and one patient had a diagnosis of anaplastic astrocytoma. One patient had her tumor located in the infratentorial region. Four patients had multilobar involvement. NTRK fusion was found in four patients (ETV6-NTRK3 fusion and TPR-NTRK1 fusion). ALK fusion was found in one patient (HMBOX1-ALK). ROS1 fusion was found in one patient (ZCCHZ8-ROS1). All patients underwent chemotherapy, with four patients switched to NTRK inhibitors and one patient to ROS1 inhibitors afterward. Surgery was performed at various time points for these patients. Two patients passed away, at 22 and 35 months of age at submission of this abstract.

Conclusions: Infantile high-grade glioma should be regarded as a unique tumor entity and a multidisciplinary approach is paramount in improving survival for this group of patients.

Keywords: Infantile; high-grade glioma; Hong Kong; case series

Acknowledgments

Funding: None.

Footnote

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://cco.amegroups.com/article/view/10.21037/cco-24-ab055/coif). The authors have no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013) and approved by the Hong Kong Hospital Authority. Because of the retrospective nature of the research, the requirement for informed consent was waived.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the noncommercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.

Cite this abstract as: Lau SNS, Cheng KFK, Ho WSW, Ku TLD, Chan CFG. AB055. Infantile high-grade glioma (IHG)—a case series of Hong Kong experience. Chin Clin Oncol 2024;13(Suppl 1):AB055. doi: 10.21037/cco-24-ab055

Article Options

Download Citation

Share